Overview

A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To determine the efficacy and safety of Sandostatin (octreotide) compared to placebo in controlling diarrhea which is a manifestation or complication of documented HIV infection and which is refractory (does not respond) to all known treatment classes.

Phase:

N/A

Details

Lead Sponsor:

Sandoz

Treatments:

Octreotide